. . . according to the findings of the Ultra-Low-dose Transdermal Estradiol Assessment, a randomized, blinded, placebo-controlled, 2-year trial involving about 400 postmenopausal women.
. . . according to the findings of the Ultra-Low-dose Transdermal Estradiol Assessment, a randomized, blinded, placebo-controlled, 2-year trial involving about 400 postmenopausal women.
The authors of the study gave the women, who had no history of breast cancer or hysterectomy, either unopposed 0.014 mg/d transdermal estradiol or an identical placebo patch.
The finding of no significant difference between treatment groups in change in percent breast density after 1 year (between-group difference, 0.1%; 95% CI, –1.3%–1.6%) or 2 years of treatment (0.8%; –0.6%–2.1%) is significant because women with high breast density are at already increased risk for breast cancer. And interventions like combination estrogen/medroxy-progesterone that further increase breast density can put women at unacceptable risk. The ultra-low-dose transdermal estradiol also improved bone density and had no negative effects on the uterus.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More